Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

immune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung and gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materia
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... -- Houston dentist , Dr. Behzad Nazari ... Invisalign. With access to this increasingly popular orthodontic ... without feeling self-conscious in the process. Invisalign offers ... of braces, but patients who choose Invisalign over ... support for their oral health and comfort during ...
(Date:7/28/2014)... ORLANDO, Fla. , July 28, 2014 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development, ... that it has filed definitive proxy materials with ... its 2014 Annual Meeting of Shareholders to be ... a.m., East Standard Time. The record date for ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences ... clinical,trial showing that KOS-1584/R1645, an epothilone under,co-development ... in patients with solid tumors.,KOS-1584/R1645 showed activity ... including activity in patients with non-small cell ...
... Investigational cancer drug Pertuzumab shows promising results ... Phase III,development initiated, BASEL, Switzerland, June 4, ... exciting new cancer medicine pertuzumab, a HER,dimerisation ... pre-treated HER2 positive breast cancer, when,combined with ...
Cached Medicine Technology:Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 2Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 3Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 4Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 5Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5
(Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... tickets for the Guinness International Champions Cup Match between ... new Yankee Stadium in the Bronx has hosted countless big ... have the charm and history of the original Yankee Stadium, ... events in the New York City metro area. , ...
(Date:7/28/2014)... Scottsdale, Ariz (PRWEB) July 28, 2014 ... closed on a new camp property in Cornville, ... provides seriously ill children with the opportunity to ... the campers and families. The organization offers a ... ages 6-15 with chronic and life threatening illnesses ...
(Date:7/28/2014)... Quincy Bioscience, makers of the nation’s leading memory ... release of the fourth edition of The Brain Health ... , The Brain Health Guide is a unique resource ... to improve memory and promote optimal aging. Rather than ... Guide provides ways to help minimize common memory lapses ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... takes humans just milliseconds to look at someone,s face and ... study finds that certain facial features seem to trigger specific ... and size of the mouth, for example, appear directly linked ... to attractiveness. The study findings suggest that first ...
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3
... Products from AnaSpec, Accelrys, Almac Diagnostics, Seahorse Biosciences, BioFortis recognized ... ... San Francisco, CA (PRWEB) March 3, 2009 ... biotech companies that have won the Third Annual Best ...
... American Journal of Epidemiology , Oregon Research Institute ... a high-density of fast food outlets was associated with ... inches in waist circumference among neighborhood residents who frequently ... associated with a decrease of 2.7 pounds in weight ...
... types of child maltreatment are robust risk factors for ... that explored the influence of social environment on the ... appears in the current issue of Addictive Behaviors ... more alcoholic drinks on a single occasion at least ...
... 3 TouchMark, a division of Delphon Industries and industry ... is offering complimentary NRE (Non-Recurring Engineering or set-up fees) on ... customer who submits a new Pad Print order will not ... our customers, loyalty to TouchMark," says Jeanne Beacham, CEO. ...
... BOSTON, March 3 Important deadlines are approaching ... settlement related to the average wholesale prices of ... for the District of Massachusetts granted preliminary approval ... In the lawsuit, In re: Pharmaceutical Industry ...
... 3 Rochester Medical Corporation (Nasdaq: ROCM ... the company,s outstanding common shares pursuant to its previously ... repurchase shares from time to time on the open ... accordance with applicable SEC guidelines and regulations. Additionally, the ...
Cached Medicine News:Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 2Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 3Health News:Fast-food density and neighborhood walkability affect residents' weight and waist size 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 3Health News:Important Deadlines Near for $21 Million Class Action Settlement That Provides Consumers With Money Back for Over 200 Prescription Drugs 2Health News:Rochester Medical Renews Share Repurchase Activity 2
...
... FLEXILOG antimony pH catheters are designed for patient ... ,All catheters are number marked at 5cm intervals ... than sixteen individual models are available spanning most ... or multi-use models with one or two sensors., ...
... The Standard VersaFlex™ disposable pH ... nurses, and clinics worldwide for evaluating ... catheters for 24-hour esophageal pH monitoring. ... the smallest diameter esophageal catheter on ...
FLEXILOG accessory....
Medicine Products: